{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/01/3304404/29489/en/AIM-ImmunoTech-Completes-Phase-2-DURIPANC-Enrollment-Milestone-Ahead-of-Schedule-Advancing-Ampligen-Toward-Critical-Pancreatic-Cancer-Clinical-Milestones.html", "message": "News view counter 769914 successfully enlarged"}